sion until posttreatment erythema occurred. Subsequently, the dose was kept constant at the minimal erythemal dose. Topical tacrolimus ointment, 0.1%, was applied concurrently to all lesions throughout the treatment period. Sun protection was recommended. Clinical photographs were obtained at baseline and every other week. Two dermatologists (J.H.L. and Y.S.J.) independently compared the photographs of the final follow-up with those at baseline and assessed the level of repigmentation using a quartile grading scale (no repigmentation, 0%; mild, 1%-24%; moderate, 25%-49%; good, 50%-74%; excellent, 75%-99%; complete, 100%). All patients signed informed consent, and the study was approved by the Ethics Committee of the Catholic Medical Center Office of Human Research Protection.
Results | The median number of treatment sessions was 23 (range, 13-47); the median treatment duration was 3.7 (range, 1.8-6.2) months; the median cumulative dose was 11 850 (range, 4400-24 450) mJ/cm 2 ; and the maximum dose was 650 (range, 400-900) mJ/cm 2 (Table) .
Eleven patients (79%) showed excellent to complete repigmentation after medians of 21 (range, 13-39) treatments and 3.7 (range, 1.8-6.1) months ( Figure) . The remaining 3 patients had good (n = 2) or moderate (n = 1) repigmentation. Repigmentation began after a median of 5 treatments (range, 4-9). A combined pattern of marginal and perifollicular repigmentation (6 [43%]) was predominant, followed by perifollicular than 48 hours, but this improved spontaneously after 3 to 4 days. No serious adverse effects stopped the treatments.
Discussion | Although narrow-band UV-B phototherapy is the most widely used treatment modality for patients with vitiligo, it is associated with unnecessary UV exposure to normal skin. 3 Because a majority of patients have limited involvement of their body surface, targeted phototherapy including a 308-nm xenon chloride excimer laser (EL) has been considered the treatment of choice for localized vitiligo.
4
In this study, we observed a marked response using a 311-nm TSL to treat patients with nonsegmental vitiligo on the face and neck. The initial response was fast, and the overall efficacy of the TSL treatment was comparable to that reported for EL treatment. 5 The therapeutic mechanism of TSL would involve immune modulation and melanocyte stimulation, as in narrow-band UV-B and EL treatment. 6 The 311-nm TSL has several advantages. It does not require the periodic gas charging that is crucial for EL maintenance. In addition, the 311-nm wavelength of TSL can penetrate deeper than the 308-nm wavelength of EL. The gain-switched 311-nm TSL is a promising option for treating vitiligo. Further research is needed, including clinical trials comparing EL and TSL.
